Comment on FR Doc # 2026-10128
James DAgostinoSupportIndividual
Summary: An individual who experiences diminished effects from generic Vyvanse medications argues that the current bioequivalency standards for generics are too low. They support the proposed action to revise manufacturing and procurement quotas to ensure cleaner and more effective medication alternatives.
After being diagnosed with adhd after missing diagnosis as a kid, I was grateful for the chance to try medication. Unfortunately only my 1st two refills worked and gave me a quality of life I never knew was an option. My psych prescribed generic vyvanse and the 1st 60 days were incredible but unfortunately each fill thereafter the quality diminished, under his guidance we tried different doses to be safe but confirmed the vastly different fillers and inactives between each generic formulation of Vyvanse we're most likely to blame for the dwindling effects of my medication even after med breaks too. The next step will be to contest insurance to cover brand name. Our government shouldn't allow generics such a window of error, 80~130% bio equivalency is absolutely an abhorrent standard to be maintaining and the USA needs to set precedent in controlled, clean, and effective medication procurement and generic alternatives